Medicine:GBP510
From HandWiki
Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | Protein subunit |
| Clinical data | |
| Routes of administration | Intramuscular |
GBP510 is a COVID-19 vaccine candidate developed by SK Bioscience and GSK.[1][2][3][4][5]
It was jointly developed by the Institute for Protein Design of the University of Washington.[6][7]
The South Korean Ministry of Food and Drug Safety began the phase III clinical trial.[8][9]
References
- ↑ "SK COVID-19 Vaccine "GBP510" CEPI "Wave2" (next-generation vaccine)ed as the first development support target". SK Bioscience. 10 December 2020. https://www.skbioscience.co.kr/en/news/news_01_01?mode=view&id=37.
- ↑ "CEPI and SK bioscience extend collaboration to develop 'next generation' COVID-19 vaccine". Coalition for Epidemic Preparedness Innovations. 9 December 2020. https://cepi.net/news_cepi/cepi-and-sk-bioscience-to-develop-next-generation-covid-19-vaccine/.
- ↑ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)". ClinicalTrials.gov. 11 February 2021. NCT04750343. Retrieved 22 April 2021.
- ↑ "Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)". ClinicalTrials.gov. 8 February 2021. NCT04742738. Retrieved 22 April 2021.
- ↑ "SK Bioscience's COVID-19 Vaccine Uses Nanoparticle Technology of University of Washington". Business Korea. 11 June 2021. http://www.businesskorea.co.kr/news/articleView.html?idxno=69418.
- ↑ "Two nanoparticle vaccines enter clinical trials – Institute for Protein Design" (in en-US). https://www.ipd.uw.edu/2021/06/two-nanoparticle-vaccines-enter-clinical-trials/.
- ↑ "CEPI funds Phase 3 trial of UW Medicine COVID-19 vaccine". 24 May 2021. https://newsroom.uw.edu/news/cepi-funds-phase-3-trial-uw-medicine-covid-19-vaccine.
- ↑ "SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing". https://www.bioworld.com/articles/510281-sk-bioscience-advances-first-south-korean-developed-covid-19-vaccine-to-late-stage-testing?v=preview.
- ↑ "SK Bioscience Starts to Administer COVID-19 Vaccines to Subjects in Phase 3 Trial". 31 August 2021. http://www.businesskorea.co.kr/news/articleView.html?idxno=75316.
 |
